


Remarks

Applicants note with appreciation the allowance of Claims 2 - 7, 9 - 14, 18 - 20, 23, 25, 26, 28, 29, 34 - 36, 40, 43 - 51, and 54 - 62. In order to advance prosecution, Applicants have canceled Claims 15-16, 21-22, 30, 52 and 53 from the present application without prejudice or disclaimer to the re-filing of the claims in a continuation application.

Claims 30 and 52 - 53 are rejected under 35 U.S.C. § 112, first paragraph because the Examiner contends that the specification "does not reasonably provide enablement for prevention of infection by HIV." Claims 30, 52 and 53 have been canceled. Therefore, the rejection is moot.

In view of the amendment and foregoing discussion, it is respectfully submitted that the present application is in condition for allowance. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted,




Kimberly H. Parker
Attorney for Applicant
Reg. No. 47,843

Date: May 13, 2005

GlaxoSmithKline
Corporate Intellectual Property Department
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel: (919) 483-8406
Fax: (919) 483-7988

Express Mail Label No.: EV332065638US
Date of Mailing: 5/13/05

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.


Patty Wilson